Healthcare Investment
Latest news, explainers and analysis on Healthcare Investment. Tracking 6 stories on Arth Vani.
Connected in the graph
Latest on Healthcare Investment
Quadria Capital Plans Major Exits via Maxivision and Aragen IPOs by 2027
Healthcare-focused private equity firm Quadria Capital is targeting 1.5x cash returns for its investors by early 2027. The firm plans to achieve this through public listings of portfolio companies like Maxivision Eye Hospital and Aragen Life Sciences.
Aster DM Healthcare to Invest ₹1,315 Crore to Expand Hospitals in Karnataka
Aster DM Quality Care has announced a massive ₹1,315 crore investment to boost healthcare infrastructure in Karnataka. The funds will be used to build new hospitals and upgrade existing facilities in Bengaluru to provide advanced medical care.
IPOBreakingManipal Health to Invest ₹4,000 Crore for 2,400 New Beds Ahead of IPO
Manipal Health Enterprises plans to invest ₹4,000 crore over the next 3-4 years to add 2,400 hospital beds, increasing its capacity by over 18%. This significant expansion comes just before its anticipated Initial Public Offering (IPO) next week.
Indian Biotech Sector Booms as Startup Count Hits 2,400; PE Investments Double
India's pharmaceutical and biotech landscape is witnessing a massive shift with private equity investments doubling to $731 million. A new report highlights that the number of biotech startups has surged to 2,400, signaling a robust pipeline for new drug development.
Pfizer Faces Dual Crisis: Stock Performance Slumps as Iconic Headquarters Decays
Pharmaceutical giant Pfizer is grappling with a significant decline in stock value alongside the physical deterioration of its former landmark building. This trend highlights the company's struggle to maintain its pandemic-era momentum in a post-COVID market.
Zydus Lifesciences Expands US Footprint with ₹1,400 Crore Assertio Acquisition
Indian pharmaceutical major Zydus Lifesciences has completed the acquisition of US-based Assertio Holdings for approximately ₹1,400 crore ($166.4 million). The move aims to strengthen Zydus's portfolio in high-value specialty drugs and cancer support therapies.
Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.